Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Topical GS-101 for treatment of corneal neovascularization

Poster Details

First Author: R.Díaz Céspedes SPAIN

Co Author(s):    S. Garcia-Delpech   A. Hervas   P. Udaondo   E. Sanz   A. Cisneros Lanuza   D. Salom     

Abstract Details


Insulin receptor substrate 1(IRS-1) is a cytoplasmic docking protein that functions as an signaling intermediate downstream of activated cell surface receptors including insulin, insulin-like growth factor 1(IGF-1), growth hormone (GH) and vascular endothelial growth factor (VEGF). GS-101 (GeneSignal, Epalinges, Switzerland) is a 25mer phosphorothioate antisense oligonucleotide with a molecular mass of 8036 Da that inhibits the expression of IRS-1.This inhibition of IRS-1 results in the prevention of neovascular growth and has been reported to prevent the angiogenic process in preclinical in vivo and in vitro experiments.The purpose of our study is to demonstrate the clinical utility of topical GS 101.


The study was done at Universitary Hospital La Fe in Valencia (Spain) and in Aiken clinic in Valencia (Spain).


We apply the topical GS101 specifically, in patients with neovascularization-related orphan indications of corneal graft rejection, retinopathy of pre-maturity and neovascular glaucoma.


We observed a decrease in vascularization in all cases of application of GS 101


This safety, tolerability and bioavailability investigation is the first step in the development of GS-101 as a novel antiangiogenic therapeutic agent.

Financial Disclosure:


Back to Poster listing